Artivion, Inc.
Artivion, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Kennesaw, GA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $441 million and a profit of $10 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.0 out of ten, 9 of 9 metrics filed: past 5.8 out of ten, present 6.5 out of ten, future 5.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.4 out of ten. +10.5% a year over 10 filed years; profitable in 4 of 10. 54th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 2.8 out of ten. Share count grew 5.6% a year. 0% of cash flow returned. Insiders: 64 sales, 0 purchases. 28th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 5.4 out of ten. ROE 2%: 2¢ of profit per shareholder dollar. Leverage 49%: owes 49¢ per asset dollar. 54th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 6.3 out of ten. top 37% of 109 in its family; net margin 2.2%. 63rd percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 9.2 out of ten. top 8% of 90 in its family for leadership; chief executive since 2014. 92nd percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.3 out of ten. bottom 43% of 104 in its family for room to expand. 43rd percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.8 out of ten. top 41% of 105 in its family for growth drivers. 59th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.9 out of ten. top 31% of 88 in its family for expectations against reality. 69th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-18 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-09-11. Filings on record since 1996. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: North America 50%, Europe the Middle East and Africa 34%, Asia Pacific 10%, Latin America 5%. By geography: Outside the United States 52%, United States 49%. As tagged in its annual report (Form 10-K, filed 2026-02-18).
Who runs it
Mackin, James P (President & CEO); Berry, Lance A (EVP, COO, CFO & Treasurer); Davis, John E (Chief Commercial Officer); Horton, Amy (VP, Chief Accounting Officer); Green, Andrew M (SVP, Regulatory and Quality); Holloway, Jean F (SVP, General Counsel); Stanton, Marshall S. (SVP, Clinical & MD Affair); Semedo, Anthony B. (director); Ackerman, Thomas F (director); Bevevino, Daniel J (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.